Diffuse midline glioma is an aggressive brain or spinal cord tumor that grows in the central structures of the nervous system. It is classified as a high-grade (grade 4) tumor under the World Health Organization’s 2021 guidelines, defined by a specific genetic change that alters how cells regulate their DNA. The median survival for all patients is approximately 9 months, and the 2-year survival rate is around 7%, making it one of the most serious diagnoses in neuro-oncology.
While historically considered a childhood cancer, particularly when it appears in the brainstem (where it was long called DIPG, or diffuse intrinsic pontine glioma), diffuse midline glioma also occurs in adults. The updated WHO classification groups all of these tumors together based on their shared molecular signature rather than just their location or the patient’s age.
What Makes This Tumor Different
The defining feature of diffuse midline glioma is a mutation that changes how cells package and read their DNA. About 60% of high-grade pediatric gliomas carry this mutation in a gene that produces a protein called histone H3, which acts like a spool that DNA wraps around. Normally, chemical tags on these spools help control which genes are turned on or off. The mutation disrupts that system in two ways simultaneously: it strips away the “off” tags across most of the genome while adding extra “off” tags at specific gene locations tied to cancer pathways.
The practical result is that cells lose normal growth controls and begin dividing unchecked. Because this reprogramming happens at such a fundamental level of gene regulation, the tumor behaves aggressively from the start and resists many conventional treatments. The WHO now formally names this tumor “diffuse midline glioma, H3K27-altered,” reflecting that the molecular change, not the tumor’s appearance under a microscope, is what defines the diagnosis.
Where It Grows
These tumors form in midline structures of the central nervous system: the pons (a region in the brainstem), the thalamus (deep in the center of the brain), the spinal cord, and occasionally the cerebellum. All of these locations sit along the body’s central axis and control vital functions, from breathing and heart rate to sensation, movement, and consciousness. That location is a major reason treatment is so difficult. Surgery in the brainstem, thalamus, or spinal cord risks devastating loss of function, so complete removal is almost never possible.
Symptoms by Location
Symptoms depend entirely on where the tumor develops. In the brainstem, early signs often include problems with coordination, difficulty swallowing, facial weakness, and double vision. These can progress quickly over weeks. Tumors in the thalamus may cause personality changes, weakness on one side of the body, or vision problems.
When the tumor grows in the spinal cord, the pattern is different: progressive weakness in the arms or legs, numbness, and loss of bowel or bladder control. Regardless of location, tumors in the brain can also block the normal flow of cerebrospinal fluid, causing a buildup of pressure inside the skull known as hydrocephalus. This produces its own set of symptoms, including persistent headaches, nausea, vomiting, blurred vision, excessive sleepiness, and seizures. In children especially, irritability may be a prominent early sign.
How It Is Diagnosed
MRI is the primary imaging tool. The tumor typically appears as an expansive mass infiltrating the midline structure where it grows, often without a clear border between tumor and healthy tissue. For tumors in the pons, imaging alone can be strongly suggestive, though a biopsy is increasingly performed to confirm the molecular diagnosis. The H3K27 alteration must be identified through molecular testing of tumor tissue to make a definitive diagnosis under current WHO criteria. This distinction matters because it separates diffuse midline glioma from other tumors that might look similar on imaging but behave differently.
Survival and Prognosis
The numbers are sobering. Across all ages, median overall survival is about 9 months from diagnosis. Interestingly, survival differs between age groups in a direction many people wouldn’t expect: children have a median survival of roughly 7 months, while adults survive a median of about 12 months. The one-year survival rate across all patients is approximately 40%, dropping to just 7% at two years.
These figures reflect the reality that no treatment to date has substantially changed the long-term trajectory for most patients. Factors that influence individual prognosis include the tumor’s exact location, how much function remains at the time of diagnosis, and, increasingly, the specific molecular subtype of the H3K27 alteration.
Treatment: What Currently Exists
Radiation therapy remains the only proven treatment that reliably provides benefit. The standard approach delivers radiation over about six weeks, and it typically improves symptoms and slows tumor growth temporarily. For brainstem tumors, median survival with radiation is approximately 12 months. Multiple clinical trials over the past four decades have tested different radiation schedules, including higher total doses delivered in smaller, more frequent sessions, but none have improved outcomes beyond the standard approach.
For patients whose condition makes six weeks of daily treatment difficult, shorter radiation courses (delivered over about two and a half weeks) have shown similar survival, giving clinicians some flexibility to tailor the schedule to a patient’s situation.
Chemotherapy has been extensively studied alongside radiation, but no drug combination has convincingly extended survival in large trials. This includes temozolomide, the chemotherapy drug that transformed treatment for adult glioblastoma but has not shown the same benefit here.
Surgery plays a limited role. Because these tumors grow in areas that control essential functions, aggressive surgical removal carries an unacceptable risk of harm. Biopsy to confirm the diagnosis is common, and some thalamic tumors may be partially debulked, but surgery alone is not a path to meaningful tumor control.
Newer Approaches in Clinical Trials
Two areas of active research have generated cautious optimism. The first is a targeted oral drug called ONC201 (dordaviprone), which works through a different mechanism than traditional chemotherapy. In an analysis of 50 patients with recurrent disease, 20% had measurable tumor shrinkage on MRI, with responses lasting a median of about 11 months. When using broader response criteria, 30% of patients showed benefit. A large phase 3 trial is now testing this drug in newly diagnosed patients to determine whether it can improve survival when added to standard treatment.
The second promising approach uses a form of immunotherapy called CAR T-cell therapy. In this treatment, a patient’s own immune cells are collected, engineered in a laboratory to recognize a molecule found on tumor cells, and then infused back into the patient. A phase 1 trial targeting a molecule called GD2 on diffuse midline glioma cells has shown that the treatment is tolerable and can produce tumor regressions. One patient achieved a complete response that lasted more than 30 months. While these are early results from a small trial designed primarily to test safety, they represent a meaningful signal for a disease where so few treatments have shown any activity at all.
Neither of these approaches is yet part of standard care, but both are further along in development than most experimental treatments that have been tried for this tumor. For families and patients navigating a diagnosis, clinical trial enrollment is often discussed early in treatment planning as a way to access these and other investigational therapies.